German pharmaceutical industry warns of €4.6bn extra burden from healthcare savings law
German pharmaceutical industry warns new healthcare savings law will impose €4.6bn extra on drugmakers via higher rebates and tougher price-volume rules.
The German pharmaceutical industry says changes approved by the Bundestag to the coalition’s healthcare savings package will shift billions more of the cost burden onto drugmakers and away from hospitals, doctors and patients. The industry association VFA calculates the sector will face about €19.2 billion in contributions from 2027 to 2030 under the amendments, compared with €14.6 billion in the cabinet draft. The dispute has sharpened ahead of a planned parliamentary vote on July 10, 2026.
VFA analysis details projected four-year impact
The Verband Forschender Arzneimittelhersteller (VFA) provided a breakdown showing the largest deviations appear in the early years of the four‑year window. According to the VFA, the industry would shoulder roughly €4.1 billion in 2027 rather than €1.2 billion, and roughly €4.6 billion in 2028 instead of €2.3 billion under the original cabinet plan. The association says the cumulative effect is an additional €4.6 billion for the sector across 2027–2030.
The VFA frames the changes as a redistribution of costs that leaves hospitals, physicians and insured people less affected while increasing direct charges on producers. Industry leaders warn the shift could alter investment decisions and long‑term commitments to research, development and manufacturing in Germany.
Manufacturer rebate doubled under amendments
One of the most consequential adjustments in the amended bill is the expansion of the statutory manufacturer rebate. The current fixed rebate of 7 percent is scheduled to rise to a fixed 15.5 percent in 2027 under the new text, more than doubling the charge in a single step. The VFA’s modelling estimates the rebate change would force drugmakers to forgo €3.2 billion in 2027 versus €1.1 billion under the cabinet variant.
Industry representatives note the change replaces the proposed dynamic discount mechanism in the cabinet draft with a fixed, larger surcharge, a shift they say has substantial short‑term effects. Supporters of the amendment argue a fixed rate improves planning certainty for payers and suppliers and that the effects balance out over the full period.
Price‑volume rule tightened and vaccine rebate increased
The draft’s price‑volume mechanism — which reduces prices when sales exceed specified revenue thresholds — was also strengthened in the amendments. Where the cabinet text envisaged a 1 percent surcharge per exceeded €100 million band, the changes raise that to 1.5 percent, a 50 percent increase. The VFA estimates the tougher price‑volume rule could raise sector losses to between €2.8 billion and €4 billion by 2030, up from prior expectations of about €1.2 billion.
Separately, the statutory rebate on vaccines would climb from 7 to 9 percent, increasing the cumulative burden on producers from roughly €600 million to €790 million, the VFA says. These measures collectively amplify the short‑term fiscal pressure the association attributes to the bill.
Industry warns of investment and supply risks
VFA President Han Steutel told industry outlets that the measures risk sending the “wrong signal” to companies evaluating Germany as a location for investment. He and other executives cite recent announcements by multinational firms that have delayed or scaled back planned investments amid what they describe as deteriorating conditions for pharmaceutical manufacturing in Germany. The VFA argues that higher mandatory discounts and unpredictable policy shifts reduce the expected returns that justify local capital expenditure.
Executives say the absence of compensatory measures — such as a location exemption that would have spared companies with on‑shore investments from higher rebates — undercuts the bill’s potential to link cost containment with industrial policy. The association contends that combining relief for payers with incentives for domestic investment would better preserve jobs and secure access to innovative medicines.
Coalition response and legal constraints cited
Government and coalition sources have rejected claims that the package unfairly targets the pharmaceutical sector. Officials note that some planned relief for hospitals, doctors and insured citizens was introduced amid a larger shortfall and that the adjustments reflect political compromise rather than a deliberate squeeze on industry. Coalition aides also argued the location exemption the VFA sought faces complicated obstacles in EU state aid and competition law and therefore could not be implemented as initially proposed.
Ministry and parliamentary spokespeople pointed out that the move from a dynamic to a fixed manufacturer rebate followed preference expressed in parts of the sector for greater predictability. They maintain that, assessed over the full period, the amended approach will not produce a net excess burden on industry.
The debate has exposed a wider legislative tension between immediate fiscal relief for the statutory health insurance system and longer‑term industrial policy goals. Lawmakers face pressure to close funding gaps while preserving incentives for research, production and supply security.
The dispute now shifts to the Bundestag vote scheduled for July 10, 2026, where members will decide whether to adopt the amended contribution‑stabilization law and its reallocation of costs. Observers say the parliamentary decision will be closely watched by investors, industry groups and health sector stakeholders for signals about Germany’s approach to balancing cost control with pharmaceutical competitiveness.
